Andrei L. Gartel

A novel FOXM1–BCL2A1 axis determines unfavorable response to venetoclax in AML

Regulation of HOX gene expression in AML

Novel FOXM1 inhibitor STL001 sensitizes human cancers to a broad-spectrum of cancer therapies

Small-molecule inhibitors targeting FOXM1: Current challenges and future perspectives in cancer treatments

Favorable outcomes of NPM1mut AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance

Novel FOXM1 inhibitor identified via gene network analysis induces autophagic FOXM1 degradation to overcome chemoresistance of human cancer cells

FOXM1-AKT Positive Regulation Loop Provides Venetoclax Resistance in AML

FOXM1: a potential therapeutic target in human solid cancers

Therapeutic Vulnerabilities of Transcription Factors in AML

Honokiol is a FOXM1 antagonist

FOXM1 contributes to treatment failure in acute myeloid leukemia

FOXM1 in Cancer: Interactions and Vulnerabilities

Nuclear FOXM1 drives chemoresistance in AML

A Novel Function of Molecular Chaperone HSP70

Proteasome inhibitors suppress the protein expression of mutant p53

ROS inhibitor <i>N</i>-acetyl-<scp>L</scp>-cysteine antagonizes the activity of proteasome inhibitors

FOX(M1) News—It Is Cancer

Combination of Oxidative Stress and FOXM1 Inhibitors Induces Apoptosis in Cancer Cells and Inhibits Xenograft Tumor Growth

Targeting FOXM1 in cancer

Suppression of FOXM1 Sensitizes Human Cancer Cells to Cell Death Induced by DNA-Damage

Combination with bortezomib enhances the antitumor effects of nanoparticle-encapsulated thiostrepton

The oncogenic transcription factor FOXM1 and anticancer therapy